Half-year report · HY
2531.TEDINET S100X1G2
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥186.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥362.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥176.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.8bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥10.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.2bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.6bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥476.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥477.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥447.8bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥189.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥176.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥287.5bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥300.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥296.5bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥60.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥83.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥54.0bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥89.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥41.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥29.4 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.98 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.55 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.3% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥15.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥7.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥9.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥9.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥702m |
| Takara Bio Groupreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥103.9bn |
| Takara Bio Groupreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥103.7bn |
| Takara Bio Groupreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥177m |
| Takara Bio Groupreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥6.7bn |
| Takara Healthcarereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.8bn |
| Takara Healthcarereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.8bn |
| Takara Healthcarereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Takara Healthcarereportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Takara Shuzo Groupreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥57.8bn |
| Takara Shuzo Groupreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥57.1bn |
| Takara Shuzo Groupreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥679m |
| Takara Shuzo Groupreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥180.4bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥179.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥857m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥196.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥186.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥15.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥395m |
| Takara Bio Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥89.0bn |
| Takara Bio Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥88.8bn |
| Takara Bio Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥227m |
| Takara Bio Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| Takara Healthcarereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| Takara Healthcarereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| Takara Healthcarereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Takara Healthcarereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥417m |
| Takara Shuzo Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.0bn |
| Takara Shuzo Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Takara Shuzo Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥504m |
| Takara Shuzo Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥170.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥170.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥732m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥186.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥176.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 504000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 227000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 732000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8827000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 9560000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -9560000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 61980000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 88979000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 19758000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 170718000000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 15382000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 186100000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -9560000000 | JPY |
| Net sales | Prior1InterimDuration | 176539000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 2623000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 6488000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 417000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 9528000000 | JPY |
| Operating income | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1399000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10928000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -395000000 | JPY |
| Operating income | Prior1InterimDuration | 10532000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 57080000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 103711000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 18794000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 179587000000 | JPY |
| Revenues from external customers | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6968000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 186556000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 186556000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 679000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 177000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 857000000 | JPY |
| Transactions with other segments | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 8629000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 9486000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -9486000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 57760000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 103889000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 18794000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 180444000000 | JPY |
| Net sales | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 15597000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 196042000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -9486000000 | JPY |
| Net sales | InterimDuration | 186556000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 2465000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 6658000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |